Is this drug the answer to cannabis addiction?
Brain disease specialist Aelis Farma has announced results from the clinical Phase IIB trial study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study population, 82% of… Read More